Warning About triCitrasol
Don't Infuse in Patients
ROCKVILLE, MD- The Food and Drug Administration (FDA) has issued a warning that triCitrasol may cause death when infused into patients. TriCitrasol is a 46.7% concentration of sodium citrate anticoagulant used to keep bloodlines open. A case has been discovered in which a patient died of cardiac arrest after triCitrasol was injected full strength into a hemodialysis permanent blood access catheter that had just been implanted. Rapid or excessive infusion of citrate solutions can cause fatal heart rhythm disruption, seizures, or bleeding due to loss of blood calcium.
TriCitrasol is manufactured by Cytosol Laboratories and is distributed by Medcomp. Both companies voluntarily recalled the product for use with blood access catheters. TriCitrasol is also used to prepare white cells for transfusion and is still available for that purpose.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
